|
Glucose regulation during risperidone and olanzapine treatment Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Glucose regulation during risperidone and olanzapine treatment conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Glucose regulation during risperidone and olanzapine treatment Clinical research trials and Glucose regulation during risperidone and olanzapine treatment healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Glucose regulation during risperidone and olanzapine treatment. Glucose regulation during risperidone and olanzapine treatment Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Glucose regulation during risperidone and olanzapine treatment clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Glucose regulation during risperidone and olanzapine treatment condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Glucose regulation during risperidone and olanzapine treatment  Glucose regulation during risperidone and olanzapine treatment
Glucose regulation during risperidone and olanzapine treatment
For Condition: Schizophrenia
Status: Recruiting
Sponsor(s): National Center for Research Resources (NCRR) , Janssen Pharmaceutica
Synopsis: The overall purpose of this research is to look at how two of the most commonly prescribed newer antipsychotic medications, risperidone and olanzapine, affect substances in the body such as glucose and insulin. Undesirable changes in blood sugar control, or glucose regulation, and type 2 diabetes can occur more commonly in individuals with schizophrenia compared to healthy subjects and subjects with other psychiatric conditions. While abnormalities in glucose regulation were first reported in schizophrenia before the introduction of antipsychotic medications, antipsychotic treatment may contribute significantly to abnormalities in glucose regulation. Attention to the way that antipsychotic medications may affect glucose regulation has increased as doctors have become more concerned in general about disease- and drug-related medical complications, including weight gain during antipsychotic treatment.
Details: This study will include 70 patients diagnosed with schizophrenia, taking either risperidone, olanzapine or haloperidol, and 20 healthy control subjects. Each subject will undergo a 4 hour glucose tolerance test. In addition, there will be a small project within the overall study to measure the effects of risperidone and olanzapine on glucose regulation as the individuals switch from their prior treatment with a conventional antipsychotic medication to either risperidone or olanzapine. Ten subjects will be studied on a typical neuroleptic at baseline then switched over a one week period to risperidone or olanzapine. The participants will be evaluated at 1 week, 4 weeks, and 12 weeks, prospectively. Each evaluation will consist of a 4 hour glucose tolerance test.
Eligibility:
Study Type: Interventional, Treatment, Open Label
Minimum Age/Maximum Age: 18 Years/60 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - meet DSM-IV criteria for schizophrenia, any type, or schizoaffective disorder; - able to give informed consent; - no medication changes for 2 weeks prior to and during the period of study; - currently taking olanzapine, risperidone, haloperidol or another typical antipsychotic
Total Enrollment:
Location and Contact Information:
Washington University *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting John Newcomer
Additional Information:
Study ID Numbers: NCRR-M01RR00036-0752; M01RR00036
Study Start Date:
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006195
Other Schizophrenia Studies:
1. A Comparison of Study Drug with Placebo and Haloperidol in Patients With Schizophrenia
2. Genetic Study of Schizophrenia
3. Switching Medication to Treat Schizophrenia
4. Molecular Genetics of Schizophrenia
5. Treatment for First-Episode Schizophrenia
Related Studies:
Other Schizophrenia Clinical Trials
Other Missouri Clinical Trials
Other St. Louis Clinical Trials
Glucose regulation during risperidone and olanzapine treatment
|
|
|
|
|
|
|
|
